Benzene-containing compound metabolic process

Across TCGA pan-cancer cohorts, RNA activity of the Benzene-containing compound metabolic process pathway differs between tumor and matched normal tissue in 15 of the 18 cancer types tested.

The strongest signal is observed in lung adenocarcinoma (LUAD), where pathway activity is lower in tumor tissue than in matched normal tissue. In most cancer types, this pathway shows higher activity in tumors, although a few cancer types, such as LUAD and KICH, show the opposite pattern, with lower activity in tumor tissue.

LUAD, KICH, and LUSC show the most reproducible tumor–normal differences in pathway activity.

Tumor vs normal pathway activity by lineage

Ranked by sampling consensus. Activity change represents the tumor-versus-normal difference in pathway activity on a log₂ scale. Positive values indicate higher pathway activity in tumor tissue. The reported p-values are derived from the corresponding differential activity tests.

Lineage	Gender	Stage	Activity change	p	Sampling consensus
LUAD	All	III,IV	−0.048	<.001	9	view →
KICH	Male	All	−0.079	<.001	8	view →
LUSC	Male	II,III,IV	−0.058	<.001	8	view →
HNSC	All	All	−0.028	<.001	8	view →
LIHC	Female	All	−0.056	<.001	7	view →
UCEC	All	III,IV	−0.103	<.001	6	view →
BRCA	All	III,IV	−0.056	<.001	6	view →
CHOL	Male	All	−0.159	<.001	5	view →
THCA	All	All	−0.029	<.001	5	view →
STAD	Male	All	−0.055	<.001	4	view →
KIRP	All	All	−0.038	.001	4	view →
ESCA	All	All	−0.077	.033	2	view →

Pink = more active in tumor, green = less active in tumor. Showing the 12 strongest of 15 lineages.

GO:0042537–LUAD

Open the LUAD breakdown →